It has been observed that there are many patients of hyertrophic cardiomyopathy than thought. Hence a new guide line is suggested for treating them.                                                    Team@CMHF

 With nearly 600,000 people affected by hypertrophic cardiomyopathy (HCM), a disease that goes largely undetected and can decrease life expectancy, the American Heart Association (AHA) and American College of Cardiology Foundation (ACCF) put forth new guidelines about recommendations on how to detect, treat and manage patients with the genetic disease.

The authors said that controversy has also stemmed from which HCM patients should be placed with an implantable cardioverter defibrillator (ICD).

The following is recommended for Class I HCM patients: Genetic testing, Electrophysiology, Stress Testing, and Cardiac MRI.

On top of the aforementioned recommendations for HCM patients, the task force recommended beta-blocker drugs be used for the treatment of symptoms in HCM patients; however, they noted that caution should be applied in patients with sinus bradycardia or severe conduction disease.

“Although much progress has been made in understanding HCM, more research is needed to present more opportunities to improve patient outcomes,” the task force concluded.

Reference:http://www.cardiovascularbusiness.com/index.php?option=com_articles&view=article&id=30603:accaha-release-new-guidelines-for-hcm